Business Wire

DAIICHI-SANKYO

27.5.2024 09:01:28 CEST | Business Wire | Press release

Share
Multidisciplinary Think Tank proposes recommendations to improve holistic cardiovascular care in Europe

Daiichi Sankyo Europe (hereafter, Daiichi Sankyo) today announced the launch of the Future of Heart Health in Europe: A Holistic Care Think Tank report. The report follows the first-of-its-kind holistic care Think Tank meeting, held earlier this year, which brought together influential representatives from various disciplines including clinicians, patient advocates, researchers, digital and media experts and policy specialists. Three strategic recommendations for incorporating a holistic approach to CV care in Europe arose from the meeting:

  • Improve lifelong support and education:
    • Improving lifelong support and education from a young age to lay a strong foundation for sustained wellness; introducing programmes in the workplace that reward physical and mental well-being.
  • Increase interdisciplinary collaboration and communication:
    • Assigning a patient case manager and embracing implementation of artificial intelligence to improve communication and coordination of interdisciplinary collaboration.
  • Changes in health policies across Europe:
    • A holistic view of CV care should be included on political agendas at a European level. Policy changes will lead to better access to preventative care, support for the adoption of a healthy lifestyle, and removal of barriers to equitable healthcare.

Across Europe, CVD is responsible for the loss of 10,000 lives every day.3 However, cardiovascular conditions are largely preventable, and there is a growing emphasis on addressing the burden of CVD through behavioural changes and risk factor management. The holistic care Think Tank included experts with a focus on behavioural and physiological factors for CVD, such as diet, exercise, and mental health. These experts play a vital role in raising awareness of the various aspects of CVD and, together, can build a more holistic picture of a person’s health that goes beyond the view of the heart alone.

"Collaborating with a diverse array of stakeholders is paramount in adopting a truly holistic approach to heart health in Europe,” said Berk Kiran, Vice President, Commercial Operations Europe, Daiichi Sankyo Europe. “By harnessing the unique perspectives and expertise of individuals across disciplines, sectors, and backgrounds, we can help forge innovative solutions that address the challenges facing cardiovascular health today. Together, we can drive meaningful change and pave the way towards a healthier future for all."

At a political level, I think that it's time to establish health promotion and cardiovascular prevention as a real priority,” said Professor Hélder Dores, Cardiologist, Portugal and member of the Think Tank. “In healthcare, I think that not only for cardiologists but for all the professionals, it’s important to amend how we’re determining an individual’s risk and to improve lifestyle, because as we know, the great majority of atherosclerotic events could be prevented if we address the underlying risk factors.

The inaugural Think Tank meeting and report form part of Daiichi Sankyo’s ongoing heart health initiative: We Care for Every Heartbeat (WC4EHB).

For further information on holistic approaches to CV health and care in Europe and to read the full report please visit our WC4EHB website: https://wecareforeveryheartbeat.com/.

-ENDS-

About We Care for Every Heartbeat

At Daiichi Sankyo we care for every heartbeat. Our goal is to protect people from cardiovascular disease and help those who suffer from it, so they can enjoy every precious moment that life has to offer. Under the WC4EHB umbrella, Daiichi Sankyo regularly publishes informational blogs designed to improve health literacy and CVD care across Europe. We have conducted awareness surveys to uncover the public perception and attitude towards heart disease. We are working with external organisations, such as The Economist and the European Nutrition for Health Alliance (ENHA), to better understand the burden of CVD in Europe, and we partner with health specialists across a range of CV-relevant professions to advocate for greater collaboration and a holistic approach in Europe. We have made a long-term commitment to invest and work tirelessly to help patients and inspire positive change in CV care. For further information on WC4EHB and our activities, visit our website: https://wecareforeveryheartbeat.com/.

About CVD in Europe

CVD – a group of disorders affecting the heart and circulatory system, which can lead to heart attacks and strokes – is the primary cause of death in Europe, accounting for 45% of all deaths in the region and responsible for more than 10,000 lives lost every day.3,4,5,6 Furthermore, a large proportion of these deaths are premature – occurring before the age of 65 years – with CVD responsible for almost a quarter of premature deaths among men and nearly a fifth among women in Europe.7 Despite its high prevalence and burden, a lack of public awareness and gaps in understanding, especially of CVD risk factors, may be preventing those at risk from making positive lifestyle changes and adopting healthy habits to help reduce their CVD risk.8

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need.

For more information, please visit www.daiichisankyo.com

References

_____________________________

1 World Health Organization. Cardiovascular Diseases (CVDs) Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Last accessed May 2024.

2 Luengo-Fernandez, R., et al. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. Eur Heart J. 2023. 00: 1–16.

3 Mach, F., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020. 41;(1): 111–188.

4 European Heart Network. European Cardiovascular Disease Statistics 2017 edition. Available at: https://ehnheart.org/wp-content/uploads/2023/07/CVD-Statistics.pdf. Last accessed May 2024.

5 European Heart Network. CVD Statistics. Available at: https://ehnheart.org/about-cvd/the-burden-of-cvd/. Last accessed May 2024.

6 Eurostat. Causes of death statistics. Available at: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Causes_of_death_statistics#Major_causes_of_death_in_the_EU_in_2020. Last accessed May 2024.

7 European Heart Network. Fighting cardiovascular disease – a blueprint for EU action. Available at: https://www.escardio.org/static-file/Escardio/Advocacy/Documents/2020%20ESC-EHN-blueprint_digital%20edition.pdf. Last accessed May 2024.

8 Daiichi Sankyo We Care for Every Heartbeat. European Survey Report of Cardiovascular Disease – Uncovering current public perceptions and attitudes towards cardiovascular disease. Available at: wecareforeveryheartbeat.com/wp-content/uploads/2023/08/European_Survey_Report_final_approved_Jul_2022.pdf. Last accessed May 2024.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240520608896/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye